BioCentury | Nov 18, 2020
Emerging Company Profile

InterVenn: liquid biopsy diagnostics based on glycoproteins

InterVenn is tapping the glycoproteome for new markers for blood-based cancer diagnostics and using machine learning to accelerate the biomarker discovery process.  The company announced Monday that...
BioCentury | Apr 29, 2020
Product Development

Thrive AACR data highlights specificity, sensitivity trade-offs for cancer screening

Data from Thrive’s prospective, multicancer blood test study makes it clear that avoiding false positives is the top priority when screening asymptomatic individuals for rare events. While that inevitably comes at the cost of sensitivity,...
BioCentury | Jan 25, 2020
Targets & Mechanisms

CAR T strategies for cracking the code in solid tumors

...HER3) (ERBB3) (EGFR3) Interleukin-13 (IL-13) receptor alpha 2 (IL-13RA2) (IL-13R) (CD213A2) Melanoma-associated antigen A4 (MAGEA4) Mesothelin Mucin 1 (MUC1) (CD227) Mucin 16 (MUC16) (CA125) Killer...
BioCentury | Jan 17, 2020
Preclinical News

Jan 16 Preclinical Quick Takes: Deerfield's Orchard partners with Yeda; Acuitas-Penn flu vaccine in newborns; plus Regeneron, Genentech-Gladstone and Banyan

...models of prostate and ovarian cancer, costimulatory bispecifics against CD28 and PSMA, or CD28 and MUC16...
...enhanced T cell activation and tumor killing by bispecific antibodies against CD3 and PSMA or MUC16...
...NMDA receptor NR2A subtype; Influenza A HA - Influenza A virus hemagglutinin; MUC16 (CA125) - Mucin 16...
BioCentury | Nov 23, 2019
Product Development

Sanofi adds in home-grown trispecific antibody technology to grow oncology franchise

...2015 immuno-oncology deal. Two of the bispecifics target BCMA and CD3, while the third targets MUC16...
...9 BCMA (TNFRSF17; CD269) - Tumor necrosis factor receptor superfamily member 17 MUC16 (CA125) - Mucin 16 Stephen...
BioCentury | Jun 21, 2019
Preclinical News

June 21 Preclinical Quick Takes: AnaptysBio targets PD-1 for immune disease; plus Forty Seven, Homology and moreBy BioCentury Staff

...antibody increased efficacy. Sanofi (Euronext:SAN; NASDAQ:SNY) has an option to license the bispecific antibody against MUC16...
...genomic data from cancer cell lines. Targets: CD123 - Interleukin-3 receptor α; MUC16 (CA125) - Mucin 16...
...Seven Inc. Homology Medicines Inc. Regeneron Pharmaceuticals Inc. Sage Bionetworks Stanford University Stemline Therapeutics Inc. Wellcome Sanger Institute Interleukin-3 (IL-3) receptor alpha (CD123) Mucin 16 (MUC16) (CA125) Phenylalanine...
BioCentury | Jan 11, 2019
Company News

Regeneron, Sanofi narrow focus of immuno-oncology deal

...necrosis factor receptor superfamily member 17; LAG3 (CD223) - Lymphocyte-activation gene 3; MUC16 (CA125) - Mucin 16...
...Business: Cancer Allison Johnson Regeneron Pharmaceuticals Inc. Sanofi Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) (CTLA4) (CD152) Lymphocyte-activation gene 3 (LAG3) (CD223) Mucin 16 (MUC16) (CA125) Programmed...
BioCentury | Jan 8, 2019
Company News

Regeneron, Sanofi narrow focus of immuno-oncology deal

...necrosis factor receptor superfamily member 17; LAG3 (CD223) - Lymphocyte-activation gene 3; MUC16 (CA125) - Mucin 16 Allison...
...Mucin 16 Allison Johnson Regeneron Pharmaceuticals Inc. Sanofi Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) (CTLA4) (CD152) Lymphocyte-activation gene 3 (LAG3) (CD223) Mucin 16 (MUC16) (CA125) Programmed...
BioCentury | Jan 4, 2019
Financial News

TCR2 seeks IPO as first program slated to enter clinic

...treat CD19-positive B cell hematological malignancies in 2H19 and for TC-220 to treat Mucin 16 (MUC16; CA125)-positive...
...venture funding since its inception in 2015. TCR2 Therapeutics Inc., Cambridge, Mass. Elizabeth S. Eaton TC-210 TCR2 Therapeutics Inc. Mesothelin Mucin 16 (MUC16) (CA125) TRuC...
BioCentury | Dec 28, 2018
Financial News

TCR2 seeks IPO as first program slated to enter clinic

...treat CD19-positive B cell hematological malignancies in 2H19 and for TC-220 to treat mucin 16 (MUC16; CA125)-positive...
...has raised $170 million in venture funding since its inception in 2015. Elizabeth S. Eaton TC-210 TCR2 Therapeutics Inc. CD19 Mesothelin Mucin 16 (MUC16) (CA125) TC-110 TC-220...
Items per page:
1 - 10 of 258